



# BLISS GVS PHARMA LIMITED

Registered Office: 102, Hyde Park, Saklvihar Road, Andheri (East), Mumbai - 400 072.

## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2013

PART - I		(Rs. in Lakhs)			
PARTICULARS	STANDALONE				
	QUARTER ENDED		YEAR ENDED		
	30.06.2013 (UNAUDITED)	31.03.2013 (AUDITED)*	30.06.2012 (UNAUDITED)	31.03.2013 (AUDITED)	
1	Income From Operations				
	(a) Net Sales (Net of Excise Duty)	7,371.75	10,012.71	6,374.16	34,810.82
	(b) Other Operating Income	185.92	250.70	59.86	557.50
	<b>Total Income From Operations (Net)</b>	<b>7,557.67</b>	<b>10,263.41</b>	<b>6,433.82</b>	<b>35,368.32</b>
2	Expenses				
	(a) Consumption of Raw Materials	3,436.28	5,606.69	3,517.49	18,849.51
	(b) Purchase of Traded Goods	159.48	52.50	60.17	360.28
	(c) (Increase)/Decrease in Stock in Trade	508.64	(94.65)	(209.42)	(511.73)
	(d) Employee Benefit Expenses	292.91	272.90	196.62	987.07
	(e) Depreciation / Amortisation	104.97	119.71	106.74	442.78
	(f) Other Expenditure	1,841.28	2,677.22	682.79	5,604.99
	<b>Total Expenses</b>	<b>6,341.54</b>	<b>8,634.39</b>	<b>4,354.39</b>	<b>25,732.90</b>
3	Profit from Operations before other Income & Finance Cost & Exceptional Items (1-2)	1,216.13	1,629.02	2,079.43	9,635.42
4	Other Income	1,617.56	731.82	394.64	1,503.28
5	Profit From Ordinary Activities Before Finance Cost (3+4)	2,833.69	2,360.84	2,474.07	11,138.70
6	Finance Cost	188.71	221.13	80.57	655.47
7	Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	2,644.98	2,139.71	2,393.50	10,483.23
8	Exceptional Items	-	-	-	-
9	<b>Profit From Ordinary Activities Before Tax (7+8)</b>	<b>2,644.98</b>	<b>2,139.71</b>	<b>2,393.50</b>	<b>10,483.23</b>
10	Tax Expense (Including Deferred Tax)	819.94	1,589.28	704.01	4,815.03
11	<b>Net Profit From Ordinary Activities After Tax (9-10)</b>	<b>1,825.04</b>	<b>570.42</b>	<b>1,689.49</b>	<b>5,668.20</b>
12	Extra Ordinary Items (Net of Tax Expenses)	-	-	-	-
13	<b>Net Profit For The Period (11-12)</b>	<b>1,825.04</b>	<b>570.42</b>	<b>1,689.49</b>	<b>5,668.20</b>
14	Paid - Up Equity Capital	1,031.47	1,031.47	1,031.47	1,031.47
15	Reserves Excluding Revaluation Reserve (As per Balance Sheet)	-	-	-	24,842.03
16	<b>Basic and Diluted EPS (Not Annualised)</b>	<b>1.77</b>	<b>0.56</b>	<b>1.64</b>	<b>5.50</b>

PART - II					
A	Particulars of Shareholding				
1	Aggregate of Non-Promoter Shareholding				
	- No. of Shares (Face Value Rs.1/- Each)	36156842	36187842	36187842	36186842
	- Percentage of Shareholding (%)	35.05	35.08	35.08	35.08
2	Promoter and Promoter Group Shareholding				
	A) Pledge/ Encumbered				
	- No. of Shares (Face Value Re.1/- Each)	-	-	-	-
	- Percentage of Shares (As % of the total share Holding of Promoter & Promoter Group)	-	-	-	-
	- Percentage of Shares (As % of the total share Capital of the Company)	-	-	-	-
	B) Non - Encumbered				
	- No. of Shares (Face Value Re.1/- Each)	66989830	66958830	66958830	66959830
	- Percentage of Shares (As % of the total share Holding of Promoter & Promoter Group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (As % of the total Share Capital of the Company)	64.95	64.92	64.92	64.92

PARTICULARS		Quarter Ended 30 June 2013			
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter			-	
	Received during the quarter			1	
	Disposed off during the quarter			1	
	REMAINING UNSOLVED AT THE END OF THE QUARTER			-	

### Notes:-

- The company operates primarily in the pharmaceutical business and hence has only one reportable segment.
- During the quarter the company has formed a subsidiary with 51% stake in the name of Lifocon Labs Private Limited which will be engaged in trading of Pharma and Healthcare Products.
- The Statutory Auditors have carried out "Limited Review" of the aforesaid results.
- The above results were reviewed by the Audit Committee & were there after approved by The Board at its meeting held on August 14th 2013.
- The figures for the Quarter Ended March 31, 2013 are the balancing figures between the Audited figures in respect of the full financial year ended March 31, 2013 and the published year to date figures up to the third Quarter Ended December 31, 2012
- Figures for the Previous Year / Quarters have been Regrouped/Rearranged wherever necessary.

FOR BLISS GVS PHARMA LIMITED  
SD/-  
S. N. KAMATH  
MANAGING DIRECTOR

Place : Mumbai  
Date : 14-08-2013

Size : 30 cm (h) X 17 cm (w)